|
|
CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non‐Hodgkinʼs lymphoma patients : results of the prospective multicenter GOA study |
|---|---|
| Author: | Turunen, Antti1,2; Partanen, Anu1; Valtola, Jaakko1; |
| Organizations: |
1Department of Medicine, Kuopio University Hospital, Kuopio, Finland 2Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland 3Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland
4Department of Medicine, Oulu University Hospital, Oulu, Finland
5Department of Oncology, Kuopio University Hospital, Kuopio, Finland 6Department of Oncology, Oulu University Hospital, Oulu, Finland 7Department of Medicine, Turku University Hospital, Turku, Finland 8Department of Internal Medicine, Tampere University Hospital, Tampere, Finland 9Department of Oncology, Tampere University Hospital, Tampere, Finland 10Nordlab, Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland 11Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland 12Finnish Medicines Agency, Kuopio, Finland 13Department of Medicine, Savonlinna Central Hospital, Savonlinna, Finland 14Department of Medicine, Central Hospital of Central Finland, Jyväskylä, Finland 15Department of Oncology, Central Hospital of Central Finland, Jyväskylä, Finland 16Laboratory Centre of Eastern Finland, Kuopio, Finland 17Department of Medicine, Kymenlaakso Central Hospital, Kotka, Finland 18Department of Medicine, North Carelia Hospital District, Joensuu, Finland |
| Format: | article |
| Version: | published version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 0.4 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2020091769957 |
| Language: | English |
| Published: |
John Wiley & Sons,
2020
|
| Publish Date: | 2020-09-17 |
| Description: |
AbstractBackground: Autologous stem cell transplantation is an established treatment option for patients with multiple myeloma (MM) or non‐Hodgkinʼs lymphoma (NHL). Study design and methods: In this prospective multicenter study, 147 patients with MM were compared with 136 patients with NHL regarding the mobilization and apheresis of blood CD34+ cells, cellular composition of infused blood grafts, posttransplant recovery, and outcome. Results: Multiple myeloma patients mobilized CD34+ cells more effectively (6.3 × 10⁶/kg vs. 3.9 × 10⁶/kg, p = 0.001). The proportion of poor mobilizers (peak blood CD34+ cell count <20 × 10⁶/L) was higher in NHL patients (15% vs. 3%, p < 0.001). Plerixafor was added to rescue the mobilization failure in 17 MM patients (12%) and in 35 NHL patients (26%; p = 0.002). The infused grafts contained more natural killer (NK) and CD19+ cells in MM patients. Blood platelet and NK‐cell counts were higher in MM patients posttransplant. Early treatment‐related mortality was low in both groups, but NHL patients had a higher late (>100 days) nonrelapse mortality (NRM; 6% vs. 0%, p = 0.003). Conclusions: Non‐Hodgkinʼs lymphoma and MM patients differ in terms of mobilization of CD34+ cells, graft cellular composition, and posttransplant recovery. Thus, the optimal graft characteristics may also be different. see all
|
| Series: |
Transfusion |
| ISSN: | 0041-1132 |
| ISSN-E: | 1537-2995 |
| ISSN-L: | 0041-1132 |
| Volume: | 60 |
| Issue: | 7 |
| Pages: | 1519 - 1528 |
| DOI: | 10.1111/trf.15820 |
| OADOI: | https://oadoi.org/10.1111/trf.15820 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3122 Cancers |
| Subjects: | |
| Funding: |
This study was supported by North Savo Hospital District VTR and EVO Funds and also Sanofi Genzyme. Dr. Turunen is grateful for the grants provided by North Savo Hospital District Research Fund, Blood Disease Research Foundation and The Finnish Medical Foundation. |
| Copyright information: |
© 2020 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
|
https://creativecommons.org/licenses/by-nc/4.0/ |